ATLAS trials: Efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections

Future Microbiology

Volumn 5, Issue 12, 2010, Pages 1765-1773

  Barriere, Steven L ^a  

^a THERAVANCE INC   (United States)

Author keywords

Complicated skin and skin structure infections; CSSSI; Gram positive; Methicillin resistant Staphylococcus aureus; MRSA; Telavancin

Indexed keywords

CREATININE; SERUM ALBUMIN; TELAVANCIN; VANCOMYCIN;

ABDOMINAL PAIN; ABSCESS; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BURN INFECTION; CELLULITIS; COMPLICATED SKIN AND SKIN STRUCTURE INFECTION; CONVALESCENCE; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROCOCCUS FAECIUM; HEART DISEASE; HUMAN; IN VITRO STUDY; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; KIDNEY DISEASE; KIDNEY FAILURE; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PRURITUS; QT PROLONGATION; RESPIRATORY TRACT DISEASE; RIGOR; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; TASTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; ULCER; UNSPECIFIED SIDE EFFECT; URINE COMPOSITION DISORDER; VOMITING; WOUND INFECTION;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS;

EID: 78650426257     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.138     Document Type: Article

References (34)

1. National Nosocomial Infections Surveillance System: National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control. 32(8), 470-485 (2004).
2. Purcell K, Fergie J: Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Childrens Hospital. Arch. Pediatr. Adolesc. Med. 159(10), 980-985 (2005).
3. Tiemersma EW, Bronzwaer SL, Lyytikinen O et al.: Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg. Infect. Dis. 10(9), 1627-1634 (2004).
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39(3), 309-317 (2004).
5. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y: Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 36(1), 53-59 (2003). (Pubitemid 36099097)
6. Engemann JJ, Carmeli Y, Cosgrove SE et al.: Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 36(5), 592-598 (2003).
7. Melzer M, Eykyn SJ, Gransden WR, Chinn S: Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin. Infect. Dis. 37(11), 1453-1460 (2003).
8. Paladino JA, Sunderlin JL, Price CS, Schentag JJ: Economic consequences of antimicrobial resistance. Surg. Infect. (Larchmt) 3(3), 259-267 (2002).
9. Moran GJ, Krishnadasan A, Gorwitz RJ et al.: Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355(7), 666-674 (2006).
10. Donnio PY, Preney L, Gautier-Lerestif AL, Avril JL, Lafforgue N: Changes in staphylococcal cassette chromosome type and antibiotic resistance profile in methicillin-resistant Staphylococcus aureus isolates from a French hospital over an 11 year period. J. Antimicrob. Chemother. 53(5), 808-813 (2004).
11. Saiman L, OKeefe M, Graham PL 3rd et al.: Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin. Infect. Dis. 37(10), 1313-1319 (2003).
12. Gonzalez BE, Rueda AM, Shelburne SA 3rd, Musher DM, Hamill RJ, Hulten KG: Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect. Control Hosp. Epidemiol. 27(10), 1051-1056 (2006).
13. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R: Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin. Infect. Dis. 42(3), 389-391 (2006).
14. Seybold U, Kourbatova EV, Johnson JG et al.: Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin. Infect. Dis. 42(5), 647-656 (2006).
15. Chang S, Sievert DM, Hageman JC et al.: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348(14), 1342-1347 (2003).
16. Wang G, Hindler JF, Ward KW, Bruckner DA: Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44(11), 3883-3886 (2006).
17. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ: Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43(13), 925-942 (2004).
18. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42(6), 2398-2402 (2004).
19. Clinical and Laboratory Standards Institute (CLSI): Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard - Sixth Edition. CLSI, Wayne, PA, USA, M7-A6 (2006).
20. Tenover FC, Moellering RC Jr: The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44(9), 1208-1215 (2007).
21. Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM: In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob. Agents Chemother. 52(7), 2647-2652 (2008).
22. Laohavaleeson S, Kuti JL, Nicolau DP: Telavancin: a novel lipoglycopeptide for serious Gram-positive infections. Expert. Opin. Investig. Drugs. 16(3), 347-357 (2007).
23. Leuthner KD, Cheung CM, Rybak MJ: Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58(2), 338-343 (2006).
24. Pankuch GA, Appelbaum PC: Postantibiotic effects of telavancin against 16 Gram-positive organisms. Antimicrob. Agents Chemother. 53(3), 1275-1277 (2009).
25. Higgins DL, Chang R, Debabov DV et al.: Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49(3), 1127-1134 (2005).
26. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S: Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49(1), 195-201 (2005).
27. Wong SL, Barriere SL, Kitt MM, Goldberg MR: Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J. Antimicrob. Chemother. 62(4), 780-783 (2008).
28. Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, Nicolau DP: Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob. Agents Chemother. 50(2), 788-790 (2006).
29. Shaw JP, Cheong J, Goldberg MR, Kitt MM: Mass balance and pharmacokinetics of [14C] telavancin following intravenous administration to healthy male volunteers. Antimicrob. Agents Chemother. 54(8), 3365-3371 (2010).
30. Stryjewski ME, Graham DR, Wilson SE et al.: Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin. Infect. Dis. 46(11), 1683-1693 (2008).
31. Stryjewski ME, Chu VH, ORiordan WD et al.: Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50(3), 862-867 (2006).
32. Stryjewski ME, ORiordan WD, Lau WK et al.: Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin. Infect. Dis. 40(11), 1601-1607 (2005).
33. McKinnon PS, Sorensen SV, Liu LZ, Itani KM: Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann. Pharmacother. 40(6), 1017-1023 (2006).
34. Vibativ, prescribing information. Theravance, Inc., CA, USA; and Astellas Pharma US, Inc., IL, USA (2009) www.astellas.us/docs/us/VIBATIV-PI- Final.pdf (Accessed 19 March 2010)